ArcticZymes Technologies announces Partnership with Biomatter

Tromsø, Norway, December 19, 2023 – ArcticZymes Technologies ASA (OSE: AZT) enters into an agreement with Biomatter (Biomatter Designs UAB) to develop new enzyme-based products.

ArcticZymes Technologies (AZT) has entered a partnership agreement with Biomatter, a leading enzyme design company. Leveraging Biomatter’s AI-driven Intelligent Architecture^TM platform, the companies will co-develop new and improved products for AZT’s enzyme portfolio. The first focus project will be to explore the SAN portfolio in terms of new functions, properties and IP.

The Intelligent Architecture^TM platform combines generative AI and physical modelling to address the current limitations of enzyme engineering accuracy and time. The unique capabilities offered by the platform enables the design of enzymes with previously unattainable functions and properties. By leveraging this technology and Biomatter’s expertise, AZT will be able to expand its offering towards new and existing customers in both the molecular tools and biomanufacturing businesses.

Michael Akoh, CEO of ArcticZymes said:

“Working with Biomatter is a very exciting step in exploring alternatives to classic protein design methods. This partnership enhances ArcticZymes biotechnology toolbox and increases our innovation capabilities. It will play a pivotal role in accelerating additions to our product portfolio. At the same time, it is in line with our strategy to seek partnership opportunities across the value chain to create long term growth”

Laurynas Karpus, co-founder and CEO of Biomatter said:

“ArcticZymes has been a long-standing enzyme supply leader, renowned for its unique enzyme portfolio. We’re excited to collaborate with AZT, harnessing our Intelligent Architecture™ platform to explore new frontiers in life sciences enzymes, and to further expand AZT’s capabilities and offerings.”

For more information, please contact:

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
The company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes Technologies under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents. For more information, please visit the website: www.arcticzymes.com.